BioSpace News Archive

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months ended September 30, 2021.

Kezar Life Sciences, Inc. (Nasdaq: KZR), today reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN).

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter of 2021.

Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System.

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA in patients with prior peripheral artery disease at risk for major adverse cardiovascular events were delivered in a Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021, which took place virtually from November 13-15, 2021.

SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Stifel 2021 Virtual Healthcare Conference on November 17.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the 2021 Jefferies London Healthcare Conference.